Rocket Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCKT research report →
Companyrocketpharma.com
Rocket Pharmaceuticals, Inc. , together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
- CEO
- Gaurav D. Shah
- IPO
- 2015
- Employees
- 299
- HQ
- Cranbury, NJ, US
Price Chart
Valuation
- Market Cap
- $320.48M
- P/E
- -1.57
- P/S
- 0.00
- P/B
- 1.38
- EV/EBITDA
- -1.51
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -70.79%
- ROIC
- -81.81%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-223,123,000 · 13.77%
- EPS
- $-2.01 · 26.37%
- Op Income
- $-228,516,000
- FCF YoY
- 11.66%
Performance & Tape
- 52W High
- $6.83
- 52W Low
- $2.19
- 50D MA
- $3.85
- 200D MA
- $3.57
- Beta
- 0.52
- Avg Volume
- 3.43M
Get TickerSpark's AI analysis on RCKT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Wilson Martin | sell | 3,361 |
| May 13, 26 | Shah Gaurav | sell | 2,728 |
| May 13, 26 | Militello John | sell | 855 |
| May 7, 26 | Chaudhuri Sarbani | sell | 17,650 |
| Feb 18, 26 | Militello John | sell | 1,157 |
| Feb 18, 26 | Shah Gaurav | sell | 5,990 |
| Feb 18, 26 | Wilson Martin | sell | 1,376 |
| Feb 13, 26 | Wilson Martin | sell | 12,253 |
| Feb 13, 26 | Militello John | sell | 3,726 |
| Feb 13, 26 | Shah Gaurav | sell | 12,279 |
Our RCKT Coverage
We haven't published any research on RCKT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RCKT Report →